2024
Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults — United States, August 2022–July 2023
Chard A, Dalton A, Diallo A, Moulia D, Deputy N, Zecca I, Quilter L, Kachur R, McCollum A, Rowlands J, Britton A, Fisher R, Chai S, Licherdell E, Still W, Morris A, Castilho J, Markus T, Morrow A, Danza P, Hansen A, Ali S, Wegner C, Weber R, Betancourt G, Zipprich J, Sutton M, Pathela P, Hawkins S, Wendel K, Feldstein L. Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults — United States, August 2022–July 2023. MMWR Morbidity And Mortality Weekly Report 2024, 73: 896-902. PMID: 39388387, PMCID: PMC11466375, DOI: 10.15585/mmwr.mm7340a2.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCase-Control StudiesHomosexuality, MaleHumansMaleMiddle AgedRisk AssessmentSARS-CoV-2Transgender PersonsUnited StatesYoung AdultConceptsCondomless receptive anal sexReceptive anal sexAnal sexUnited StatesCase-patientsControl patientsAssociated with sexual contactSex practicesSexually active personsTransgenderAssociated with transmissionSexual contactAdjusted oddsMSMMenVaccination coverageActive personsNonintimatesVaccinePatientsMpoxVaccine promotionMultifaceted approachSexIntimate
2023
Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase-Control StudiesHomosexuality, MaleHumansMaleMonkeypoxSexual and Gender MinoritiesSmallpox VaccineUnited StatesConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory Committee